Natera Q2 2023 Earnings Presentation - August 3, 2023

Natera reported strong Q2 2023 results with 32% YoY revenue growth to $261M and 45.2% gross margin, raising full-year guidance to $1.015B-$1.035B. The presentation highlights clinical validation milestones for Prospera, Signatera, and NIPT tests, plus progress on oncology testing with 84K tests performed and enrollment completion in the Phase III ALTAIR colorectal cancer study. The company also achieved favorable legal outcomes and reduced projected cash burn by $150M year-over-year.